Objectives To contrast the influence of combination therapy of chronically inhaling budesonide/forrnoterol and salmeterol/flutieasone on lung function, health-relatod quality of life to patients with moderate or severe chronic obstructive pulmonary disease (COPD) of stabilization period. Methods 60 cases with moderate or severe COPD cases of stabilization period were randomly divided into control group( terbutaline aerosol treatment group)20 cases、budesonide/formoterol treatment group 20 cases、 salmeterol/flutieasone treatment group 20 cases by a randomized,one-blind way. The observing cycle was 6 months. To compare the index of three groups including The St. George's Hospital Respiratory Questionnaire, SGRQ) 、lung function and walking distance of 6 minutes between pretherapy and post-treatment. Results Compared to the control group, the score of health-related quality of life、 the lung function、 Walkingdistaneeof6minute in in treatment group all had obviously been improved after 6 months'therapy,the difference had statistically significance( P ＜ 0.05 ). The comparison of salmeterul/flutieasone treatment group and budosonide/formoterol treatment group had no statistically significance. Conclusion the effect of budesonide/formoterol, salmeterol/flutieasone TheraPy on Outcome in moderate or severe stable COPD is similar.%目的 比较长期联合吸入布地奈德/福莫特罗和沙美特罗/氟替卡松对中重度稳定期COPD病人的肺功能、生活质量的影响.方法 60例中重度稳定期COPD病人随机分为规律吸入布地奈德/福莫特罗(160 μg/4.5 μg)20例,规律吸入沙美特罗/氟替卡松(50 μg/250 μg)20例,按需吸入特布他林组20例(对照组).测定三组试验前及试验后6个月圣*乔治(St*George)呼吸疾病问卷(SGRQ)的评分、6分钟行走距离(6-MWD)、肺功能.结果 布地奈德/福莫特罗组与沙美特罗/氟替卡松组治疗后较对照组生活质量改善、6-MWD增加、肺功能改善,差异有统计学意义(P＜0.05);布地奈德/福莫特罗组与沙美特罗/氟替卡松组间比较,差异无统计学意义(P＞0.05).结论 与沙美特罗/氟替卡松一样,规律吸入布地奈德/福莫特罗能改善中重度稳定期COPD病人的临床症状、运动耐力和肺功能.
展开▼
